ProHealth health Vitamin and Natural Supplement Store and Health
Log In  |  My Account  |  View Cart  View Your ProHealth Vitamin and Supplement Shopping Cart
800-366-6056  |  Contact Us  |  Help

|
|
|
|

Trending News

New Lyme guidelines promote options and informed choice

Phases of clinical depression could affect treatment

“Worm pill” could ease autoimmune disease symptoms

Eating Baked or Broiled Fish Weekly Boosts Brain Health, Pitt Study Says

Preserving Cognitive Function with Aging

Scientists Look for Biomarkers to Improve Treatment of Painful Bladder Condition

New culprit identified in metabolic syndrome

9 Health Benefits of Cucumbers

Low vitamin D levels linked to increased risks after noncardiac surgery

Irritable Bowel Syndrome: Unlocking the Secrets of Peppermint, Acacia and Fennel

 
Print Page
Email Article

Topiramate for Migraine Prevention in a Naturalistic Setting: Results From an Open Label, Flexible Dose Study – Source: Headache, Oct 5, 2009

  [ 26 votes ]   [ Discuss This Article ]
By G Nelles, et al. • www.ProHealth.com • October 9, 2009


[Note: Topiramate is an anticonvulsant drug with FDA approval for treatment of seizure disorders and migraine prevention, and is sometimes prescribed off-label as an antidepressant.]

Background: Headaches are one of the most common neurological symptoms, and migraines are the most common primary headache disorder. The global prevalence of migraines is around 10% and the condition is associated with a high burden of disease.

Despite an abundance of good quality evidence, only 1 in 5 of patients who fulfill the criteria for preventive migraine therapy are appropriately treated.

Data on patient outcomes with preventive medication derive mostly from specialized academic centers, which contrasts with normal clinical practice where the majority of patients are treated outside tertiary care centers.

Objective: To explore tolerability, safety and efficacy outcomes of patients receiving topiramate for migraine prevention in a naturalistic setting.

Methods: After a 4-week prospective baseline, patients with a diagnosis of migraine according to International Headache Society criteria and eligible for migraine prevention were treated with flexible dosing of topiramate for 24 weeks (core phase), and optionally for a total of 48 weeks.

The primary safety analysis included adverse events (AEs) during the core phase.

For the main efficacy measures, the absolute changes from baseline to end of core phase as well as last follow-up visit were calculated for:

• Migraine days per 4 weeks,

• Migraine attacks per 4 weeks,

• Mean maximum visual analogue scale of migraine headache per 4 weeks

• And mean maximum pain intensity of migraine headache (4-point scale) per 4 weeks.

• In addition, changes in individual quality of life aspects were captured.

Results:
The intention-to-treat population (ITT) consisted of 161 patients (90.7% female, mean age 45.7 +/- 11.1 years). Topiramate median [average] dose was 45.7 mg/day at endpoint.

Some 74.1% of patients reported treatment emergent adverse events, most frequently paresthesias [“pins & needles”/numbness] (18.4%) and nausea (12.4%). Some 20.0% of patients withdrew from the study due to AEs.

• The mean number of migraine days per 4 week decreased from 6.2 +/- 3.9 days at baseline to 3.9 +/- 3.5 days at last core visit (P < .001).

• Mean maximum pain intensity per 4 week changed from 7.0 +/- 2.3 at baseline to 4.7 +/- 3.2 at last visit core phase (P < .001).

• Consumption of triptans and analgesics reduced during the course of the core phase (P < .005).

• Fifty-one percent of all patients experienced at least a 50% reduction in migraine days during the core phase.

Conclusion:
Topiramate used for migraine prevention in non-academic institutions is generally safe, well tolerated and results in good control of migraine headaches and improvement in several aspects of quality of life.

Source: Headache, Oct 5, 2009. PMID: 19804392, by Nelles G, Delbrück A, Schulze L, Kademann B, Bornhoevd K, Schäfer S, Schäuble B. Neurology Outpatient Clinic, St. Elisabeth Krankenhaus Köln, Cologne; Private Practices, Celle, Belgersheim, and Leipzig; Janssen-Cilag EMEA, Neuss; AMS, Mannheim, Germany.




Please Discuss This Article:   Post a Comment 



[ Be the first to comment on this article ]




 
Free Chronic Fatigue Syndrome and Fibromyalgia Newsletters
Subscribe to
Our FREE
Newsletter
Subscribe Now!
Receive up-to-date ME/CFS & Fibromyalgia treatment and research news
 Privacy Guaranteed  |  View Archives

Save on Your Next Order

Featured Products

Ultra EPA  - Fish Oil Ultra EPA - Fish Oil
Ultra concentrated source of essential fish oils
Energy NADH™ 12.5mg Energy NADH™ 12.5mg
Improve Energy & Cognitive Function
Optimized Curcumin Longvida® by ProHealth Optimized Curcumin Longvida® by ProHealth
Supports Cognition, Memory & Overall Health
Vitamin D3 Extreme™ by ProHealth Vitamin D3 Extreme™ by ProHealth
50,000 IU Vitamin D3 - Prescription Strength
Mitochondria Ignite™ with NT Factor® Mitochondria Ignite™ with NT Factor®
Reduce Fatigue up to 45%

Natural Remedies

Front Line Defense Against Colds & Flu - Support for Healthy Immune System Balance Front Line Defense Against Colds & Flu - Support for Healthy Immune System Balance
A Breakthrough for Mitochondrial Dysfunction A Breakthrough for Mitochondrial Dysfunction
Magnesium + Malic Acid: One-Two Punch for Pain & Fatigue Magnesium + Malic Acid: One-Two Punch for Pain & Fatigue
"It's Not Easy Being Green" - But It Is Healthy
VIDEO: Healthy Eating and Fibromyalgia VIDEO: Healthy Eating and Fibromyalgia

FIBROMYALGIA RESOURCES
What is Fibromyalgia?
Fibromyalgia 101
Fibromyalgia Symptoms
Fibromyalgia Treatments
| CFS RESOURCES
What is CFS?
ME/CFS 101
ME/CFS Symptoms
ME/CFS Treatments
| FORUMS
Fibromyalgia
ME/CFS
ADVANCED MEDICAL LABS
WHOLESALE  |  AFFILIATES
GUARANTEE
CONTACT US
PRIVACY
RSS
SITE MAP
ProHealth on Facebook  ProHealth on Twitter  ProHealth on Pinterest  ProHealth on Google Plus
Credit Card Processing